FDA Clears ARISTOCORT FORTE Injectable Suspension for Approval via Abbreviated New Drug Applications

Summary

The FDA has determined that ARISTOCORT FORTE Injectable Suspension (triamcinolone diacetate, 40 mg/mL) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for approval of abbreviated new drug applications (ANDAs) for this formulation.